Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at AAO 2021
Shots:
- The P-Ib clinical trial evaluates the safety & tolerability of IBI302 multi-intravitreal injection in 18 patients with nAMD
- The results showed an improvement in visual acuity & reduction in retinal edema were observed @4wks. after three loading treatments. The therapy was safe and well-tolerated with no report of dose-limiting toxicity, & no treatment-related serious AEs were observed
- IBI302 is a bispecific anti-VEGF & anti-complement recombinant fully human fusion protein which has developed by Innovent. The company to investigate the efficacy of IBI302 on retinal fibrosis and macular atrophy along with visual acuity and retinal thickness improvement in the next study
Ref: PR Newswire | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com